Journal article
Biomarkers for PVR in rhegmatogenous retinal detachment.
- Zandi S Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik am Lindenhof-Spital, Bern, Switzerland.
- Pfister IB Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik am Lindenhof-Spital, Bern, Switzerland.
- Traine PG Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik am Lindenhof-Spital, Bern, Switzerland.
- Tappeiner C Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Despont A Department for Biomedical Research, University of Bern, Bern, Switzerland.
- Rieben R Department for Biomedical Research, University of Bern, Bern, Switzerland.
- Skowronska M Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik am Lindenhof-Spital, Bern, Switzerland.
- Garweg JG Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik am Lindenhof-Spital, Bern, Switzerland.
- 2019-04-04
Published in:
- PloS one. - 2019
Aged
Biomarkers
Cytokines
Female
Humans
Male
Middle Aged
Retinal Detachment
Vitreoretinopathy, Proliferative
English
PURPOSE
Various profibrotic and proinflammatory cytokines have been found upregulated in uncomplicated primary retinal detachment (pRD), but without providing a uniform picture. Here, we compare the cyto- and chemokine profiles in pRD with and without proliferative vitreoretinopathy (PVR) in an attempt to unravel relevant differences not in single cytokines, but in the cytokine profiles at diagnosis.
METHODS
Undiluted vitreous fluid (VF) was obtained at the beginning of surgery from 174 eyes with pRD without relevant PVR (maximally grade B; group 1; n = 81) and with moderate or advanced PVR requiring a gas tamponade (group 2; n = 49) or silicon oil filling (group 3; n = 44). VF of eyes undergoing macular hole (MH) surgery served as controls (group 4; n = 26). Forty-three cytokines were quantified in parallel using a multiplex cytokine analysis system (Bioplex). For all comparisons we applied Holm's correction to control for multiple comparisons.
RESULTS
44.9% of group 2 eyes presented grade C1 and 55.1% C2-C3, whereas 86.4% of group 3 eyes exhibited a PVR grade of C2-D. CCL19 was the only cytokine that displayed higher concentrations in the vitreous of eyes with PVR C1 compared to lower PVR grades. Eyes with PVR C2-D showed higher levels of CCL27, CXCL6, IL4, IL16, CXCL10, CCL8, CCL22, MIG/CXCL9, CCL15, CCL19, CCL 23 and CXCL12 compared to controls. Interestingly, no difference of cytokine levels was detected between C1 and C2-D PVR.
CONCLUSIONS
CCL19 may represent a potential biomarker for early PVR progression that holds promise for future diagnostic and therapeutic applications.
Various profibrotic and proinflammatory cytokines have been found upregulated in uncomplicated primary retinal detachment (pRD), but without providing a uniform picture. Here, we compare the cyto- and chemokine profiles in pRD with and without proliferative vitreoretinopathy (PVR) in an attempt to unravel relevant differences not in single cytokines, but in the cytokine profiles at diagnosis.
METHODS
Undiluted vitreous fluid (VF) was obtained at the beginning of surgery from 174 eyes with pRD without relevant PVR (maximally grade B; group 1; n = 81) and with moderate or advanced PVR requiring a gas tamponade (group 2; n = 49) or silicon oil filling (group 3; n = 44). VF of eyes undergoing macular hole (MH) surgery served as controls (group 4; n = 26). Forty-three cytokines were quantified in parallel using a multiplex cytokine analysis system (Bioplex). For all comparisons we applied Holm's correction to control for multiple comparisons.
RESULTS
44.9% of group 2 eyes presented grade C1 and 55.1% C2-C3, whereas 86.4% of group 3 eyes exhibited a PVR grade of C2-D. CCL19 was the only cytokine that displayed higher concentrations in the vitreous of eyes with PVR C1 compared to lower PVR grades. Eyes with PVR C2-D showed higher levels of CCL27, CXCL6, IL4, IL16, CXCL10, CCL8, CCL22, MIG/CXCL9, CCL15, CCL19, CCL 23 and CXCL12 compared to controls. Interestingly, no difference of cytokine levels was detected between C1 and C2-D PVR.
CONCLUSIONS
CCL19 may represent a potential biomarker for early PVR progression that holds promise for future diagnostic and therapeutic applications.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1371/journal.pone.0214674
- PMID 30943234
- Persistent URL
- https://sonar.ch/global/documents/177939
Statistics
Document views: 22
File downloads: